Ferrer-Font L - Search Results

1

Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.

Ferrer-Font L, Arias-Ramos N, Lope-Piedrafita S, Julià-Sapé M, Pumarola M, Arús C, Candiota AP. Ferrer-Font L, et al. NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3748. Epub 2017 Jun 1. NMR Biomed. 2017. PMID: 28570014

2

Protein Kinase CK2 Content in GL261 Mouse Glioblastoma.

Ferrer-Font L, Alcaraz E, Plana M, Candiota AP, Itarte E, Arús C. Ferrer-Font L, et al. Pathol Oncol Res. 2016 Jul;22(3):633-7. doi: 10.1007/s12253-015-9987-7. Epub 2015 Oct 14. Pathol Oncol Res. 2016. PMID: 26466942 Free article.

3

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C, Candiota AP. Ferrer-Font L, et al. Pharmaceuticals (Basel). 2017 Feb 12;10(1):24. doi: 10.3390/ph10010024. Pharmaceuticals (Basel). 2017. PMID: 28208677 Free PMC article.

4

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.

Arias-Ramos N, Ferrer-Font L, Lope-Piedrafita S, Mocioiu V, Julià-Sapé M, Pumarola M, Arús C, Candiota AP. Arias-Ramos N, et al. Metabolites. 2017 May 18;7(2):20. doi: 10.3390/metabo7020020. Metabolites. 2017. PMID: 28524099 Free PMC article.

5

Improving Ribosomal RNA Integrity in Surgically Resected Human Brain Tumor Biopsies.

Castells Domingo X, Ferrer-Font L, Davila M, Candiota AP, Simões RV, Fernández-Coello A, Gabarrós A, Boluda S, Barceló A, Ariño J, Arús C. Castells Domingo X, et al. Biopreserv Biobank. 2016 Apr;14(2):156-64. doi: 10.1089/bio.2015.0086. Epub 2016 Feb 17. Biopreserv Biobank. 2016. PMID: 26886080

6

Immunophenotyping challenging tissue types using high-dimensional full spectrum flow cytometry.

Ferrer-Font L, Burn OK, Mayer JU, Price KM. Ferrer-Font L, et al. Methods Cell Biol. 2024;186:51-90. doi: 10.1016/bs.mcb.2024.02.014. Epub 2024 Mar 7. Methods Cell Biol. 2024. PMID: 38705606

7

Panel Design and Optimization for Full Spectrum Flow Cytometry.

Ferrer-Font L, Small SJ, Hyde E, Pilkington KR, Price KM. Ferrer-Font L, et al. Methods Mol Biol. 2024;2779:99-124. doi: 10.1007/978-1-0716-3738-8_6. Methods Mol Biol. 2024. PMID: 38526784

8

Combinatorial antibody titrations for high-parameter flow cytometry.

Burn OK, Mair F, Ferrer-Font L. Burn OK, et al. Among authors: ferrer font l. Cytometry A. 2024 May;105(5):388-393. doi: 10.1002/cyto.a.24828. Epub 2024 Feb 6. Cytometry A. 2024. PMID: 38317641

9

Guidelines for establishing a cytometry laboratory.

Belkina AC, Roe CE, Tang VA, Back JB, Bispo C, Conway A, Chakraborty U, Daniels KT, de la Cruz G, Ferrer-Font L, Filby A, Gravano DM, Gregory MD, Hall C, Kukat C, Mozes A, Ordoñez-Rueda D, Orlowski-Oliver E, Pesce I, Porat Z, Poulton NJ, Reifel KM, Rieger AM, Sheridan RTC, Van Isterdael G, Walker RV. Belkina AC, et al. Among authors: ferrer font l. Cytometry A. 2024 Feb;105(2):88-111. doi: 10.1002/cyto.a.24807. Epub 2023 Nov 8. Cytometry A. 2024. PMID: 37941128

10

Shared resource lab (SRL) strategies for supporting high-dimensional cytometry data analysis.

Gravano DM, Rieger AM, Nettenstrom L, Hall C, Ferrer-Font L. Gravano DM, et al. Among authors: ferrer font l. Cytometry A. 2023 Dec;103(12):947-952. doi: 10.1002/cyto.a.24800. Epub 2023 Oct 6. Cytometry A. 2023. PMID: 37800362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page